Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILB-H82E9 | Human | Biotinylated Human IL-1 beta / IL-1F2 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILB-H51H3 | Human | Human IL-1 beta / IL-1F2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
ILB-C51H3 | Cynomolgus | Cynomolgus IL-1 beta / IL-1F2 Protein, His Tag | ![]() |
![]() ![]() |
|
ILB-M51H3 | Mouse | Mouse IL-1 beta / IL-1F2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILA-H525c | Human | Human IL-1 beta / IL-1F2 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILB-H4110 | Human | Human IL-1 beta / IL-1F2 Protein, Tag Free (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Human IL-1 RII, Fc Tag (Cat. No. IL2-H4256) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-1 beta, His Tag (Cat. No. ILB-H51H3) with an affinity constant of 0.571 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rilonacept | KPL-914; RGN-303 | Approved | Regeneron Pharmaceuticals Inc | Arcalyst | United States | Pericarditis | Regeneron Pharmaceuticals Inc | 2008-02-27 | Anemia; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn; Arthritis, Juvenile; Hyperlipoproteinemia Type I; Pericarditis; Cryopyrin-Associated Periodic Syndromes; Gout; Renal Insufficiency, Chronic | Details |
Diacerein | AC-201; AC-203; Art-50; SF-277; CCP-020; KW-4800; AC-201CR | Approved | Verboril, Art, 安必丁, Artrodar, Artrolyt, Cartivix, Fisiodar | Diabetes Mellitus, Type 2; Epidermolysis Bullosa Simplex; Epidermolysis Bullosa; Epidermolysis Bullosa, Junctional; Osteoarthritis, Knee; Diabetes Complications; Pemphigoid, Bullous; Osteoarthritis; Arthritis; Osteoarthritis, Hip; Diabetes Mellitus; Epidermolysis Bullosa Dystrophica | Details | |||||
PG-201 | PG-201 | Approved | Viromed | Layla | South Korea | Osteoarthritis | Pmg Pharm Co Ltd | 2012-01-01 | Osteoarthritis, Knee; Osteoarthritis | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular | Details |
Canakinumab | ACZ-885 | Approved | Novartis Pharma Ag | Ilaris | United States | Still's Disease, Adult-Onset | Novartis Pharma Ag | 2009-06-17 | Carcinoma, Non-Small-Cell Lung; Arthritis, Gouty; Sarcoidosis, Pulmonary; Colorectal Neoplasms; Osteoarthritis, Knee; Cognitive Dysfunction; Alzheimer Disease; Gout; Pulmonary Disease, Chronic Obstructive; Cryopyrin-Associated Periodic Syndromes; Diabetes Mellitus; Aortic Aneurysm, Abdominal; Anemia, Sickle Cell; Peripheral Arterial Disease; Adenocarcinoma; Macular Degeneration; Behcet Syndrome; Melanoma; Muckle-Wells Syndrome (MWS); Diabetes Mellitus, Type 1; Still's Disease, Adult-Onset; Prediabetic State; Atherosclerosis; Diabetes Mellitus, Type 2; Mevalonate Kinase Deficiency; Triple Negative Breast Neoplasms; Hereditary Autoinflammatory Diseases; Familial Mediterranean Fever; Arthritis, Rheumatoid; Myelodysplastic Syndromes; Arthritis, Juvenile; Mucocutaneous Lymph Node Syndrome; Tumor necrosis factor receptor associated periodic syndrome; Hyperimmunoglobulin D syndrome; Dry Eye Syndromes | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Tissue Adhesions; Post-surgical adhesions; Cicatrix | Details |
Recombinant humanized monoclonal antibody antiIL-1β | SSGJ-613 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Tumor necrosis factor receptor associated periodic syndrome; Arthritis, Juvenile; Inflammation | Details |
Ajulemic acid | CT-3; HU-239; IP-751; DMH-11C; JBT-101; CPL-7075; DMH-THC-11-OIC | Phase 3 Clinical | Corbus Pharma | Cystic Fibrosis; Dermatomyositis; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Scleroderma, Diffuse | Details |
ALTA-2530 | OSP-101; ALTA-2530 | Clinical | Details | ||
Gevokizumab(Xoma) | XMA-005.2; AB-7; XOMA-052; S-78989; VPM-087 | Phase 3 Clinical | Xoma | Diabetes Mellitus, Type 1; Acne Vulgaris; Pyoderma Gangrenosum; Diabetes Mellitus, Type 2; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Arthritis, Rheumatoid; Colorectal Neoplasms; Uveitis; Osteoarthritis; Labyrinth Diseases; Panuveitis; Behcet Syndrome | Details |
Kinnazumab | Phase 2 Clinical | Changchun Genescience Pharmaceutical Co Ltd | Solid tumours; Arthritis, Juvenile; Arthritis, Gouty; Gout | Details | |
lutikizumab | ABT-981 | Phase 2 Clinical | Abbvie Inc | Osteoarthritis, Knee; Osteoarthritis; Hidradenitis Suppurativa | Details |
DLX-2323 | DLX-2323 | Phase 1 Clinical | Delenex Therapeutics | Inflammation | Details |
Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune | Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
RPH-104 | RPH-104 | Phase 3 Clinical | Trpharm | Familial Mediterranean Fever; Schnitzler Syndrome; ST Elevation Myocardial Infarction; Coronavirus Disease 2019 (COVID-19); Pericarditis; Gout | Details |
AK-114 | AK-114; AK114 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Inflammation; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.